Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.75 USD
Change Today +0.24 / 9.56%
Volume 18.3K
ROKA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

roka bioscience inc (ROKA) Snapshot

Open
$2.69
Previous Close
$2.51
Day High
$2.86
Day Low
$2.50
52 Week High
09/2/14 - $12.00
52 Week Low
08/24/15 - $2.20
Market Cap
49.6M
Average Volume 10 Days
28.2K
EPS TTM
$-2.93
Shares Outstanding
18.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROKA BIOSCIENCE INC (ROKA)

Related News

No related news articles were found.

roka bioscience inc (ROKA) Related Businessweek News

No Related Businessweek News Found

roka bioscience inc (ROKA) Details

Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include molecular tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin- producing E.coli, and Listeria monocytogenes, as well as related consumable supplies. It serves food processors, third-party contract testing laboratories, and government regulatory authorities. The company was founded in 2009 and is based in Warren, New Jersey.

110 Employees
Last Reported Date: 03/27/15
Founded in 2009

roka bioscience inc (ROKA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $583.6K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $371.6K
Senior Vice President and General Manager
Total Annual Compensation: $371.6K
Compensation as of Fiscal Year 2014.

roka bioscience inc (ROKA) Key Developments

Roka Bioscience, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Roka Bioscience, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. Revenue for the quarter ended June 30, 2015 was $1.5 million compared with $1.4 million for the second quarter of 2014 and $1.5 million for the first quarter of 2015. Net loss for the second quarter of 2015 was $9.2 million, or $0.54 per basic and diluted share, compared with a net loss of $7.3 million, or $11.28 per basic and diluted share, in the second quarter of 2014. The company reported loss from operations of $8,518,000, loss before income taxes of $9,236,000 against $7,000,000 and $7,337,000 respectively a year ago. Revenue for the six months ended June 30, 2015 was $3.0 million compared with $2.2 million for the six months ended June 30, 2014. Net loss for the six months ended June 30, 2015 was $18.1 million, or $1.05 per basic and diluted share, compared with a net loss of $15.7 million, or $24.88 per basic and diluted share, in the six months ended June 30, 2014. The company reported loss from operations of $16,911,000, loss before income taxes of $14,369,000 against $18,101,000 and $15,716,000 respectively a year ago.

Roka Bioscience Appoints Nicholas J. Valeriani to its Board of Directors

Roka Bioscience, Inc. announced that Nicholas J. Valeriani has been appointed to its board of directors. Since 2012, Mr. Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute. Mr. Valeriani has announced plans to retire from the organization's chief executive position, effective September 3, 2015, however he will remain on the Institute's board of directors and will join the Gary and Mary West Health Policy Center's board. Prior to joining West Health, Mr. Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee.

Roka Bioscience, Inc. to Report Q2, 2015 Results on Aug 13, 2015

Roka Bioscience, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROKA:US $2.75 USD +0.24

ROKA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.21 USD +0.31
Bio-Rad Laboratories Inc $139.52 USD -1.74
BioMerieux €102.05 EUR +1.30
EI du Pont de Nemours & Co $51.84 USD -0.18
Neogen Corp $51.96 USD -0.16
View Industry Companies
 

Industry Analysis

ROKA

Industry Average

Valuation ROKA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.2x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROKA BIOSCIENCE INC, please visit www.rokabio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.